Cemiplimab plus chemo and other immune treatment for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This Phase 1 trial tests how well cemiplimab (an immune treatment) can work when combined with chemotherapy and an additional immunotherapy for certain head and neck cancers. It may help shrink the cancer and improve outcomes, while also checking safety and dosing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed head and neck squamous cell cancer (from the mouth, throat, nasal area, sinuses, voice box, or lower throat).
- Your cancer can be removed with surgery, and it has not spread to distant organs on scans (M0).
- Your cancer stage fits specific limits (T1 with N2–3, T2 with N1–3, or T3/T4a with any N).
- You have not had prior radiation or any treatment using medicines (systemic therapy) for this head and neck cancer.
- You must be healthy enough for treatment: hemoglobin >9, neutrophils >1.5, platelets >100, kidney and liver tests within limits, and you can carry out daily activities (performance status <1).
- You generally should not have conditions that weaken the immune system or need strong immune-suppressing medications (steroids/immunosuppressants) recently; some mild conditions are allowed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a second immunotherapy drug (CDX-1140) to the standard immunotherapy cemiplimab before surgery is better than cemiplimab alone for people with stage III-IV head and neck cancer that can be removed with surgery.
This trial compares two different immunotherapy approaches for people with HPV-positive oropharyngeal cancer who have completed initial treatment like surgery, radiation, or chemotherapy. The goal is to see which option works better to keep the cancer from coming back, and eligibility is determined by a special blood test that detects HPV DNA.
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus a targeted therapy (cetuximab) for people with advanced head and neck cancer that has gotten worse after treatment with pembrolizumab (with or without initial chemotherapy). The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
This Phase 1 trial tests cemiplimab (an immune system medicine) given with “induction” chemotherapy before the main treatment for locally advanced squamous cell head and neck cancer. It’s designed to see how well this treatment is tolerated and to learn about immune responses that may help future patients.
This Phase 2 trial studies whether cemiplimab (with or without chemotherapy first) can improve treatment for HPV-positive oropharynx throat cancer. It also uses lab “biomarkers” to help guide which treatment you get next.
This trial tests a combination of two immunotherapy drugs (cemiplimab and fianlimab) for people with newly diagnosed, advanced head and neck cancer that hasn't spread to distant parts of the body. The goal is to see if this treatment can help shrink or control the cancer.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.